Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
United Therapeutics Corporation
UTHR
$475.45
Name : United Therapeutics Corporation
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $20,392,380,416.00
EPSttm : 26.92
finviz dynamic chart for UTHR
United Therapeutics Corporation
$475.45
0.69%
$3.24
UTHR — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

6.76

Margin Of Safety %

6

Put/Call OI Ratio

0.97

EPS Next Q Diff

-0.57

EPS Last/This Y

-4.06

EPS This/Next Y

2.51

Price

475.61

Target Price

637.92

Analyst Recom

1.65

Performance Q

-12.39

Upside

29.4%

Beta

0.5

Ticker: UTHR




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-08-28UTHR515.820.740.7053925
2026-08-31UTHR510.550.743.7954139
2026-09-02UTHR492.210.741.4454171
2026-09-03UTHR490.050.740.0254290
2026-09-04UTHR487.830.740.3554364
2026-09-08UTHR498.250.750.3354473
2026-09-09UTHR506.860.740.9154772
2026-09-10UTHR504.040.730.0354991
2026-09-11UTHR497.180.730.1955021
2026-09-14UTHR503.050.724.9255428
2026-09-15UTHR500.340.730.1755464
2026-09-16UTHR498.550.7296.0555501
2026-09-17UTHR497.590.730.2455817
2026-09-18UTHR494.540.731.0055988
2026-09-21UTHR493.270.971.1535573
2026-09-22UTHR497.550.980.4941415
2026-09-23UTHR489.290.972.5641584
2026-09-24UTHR472.230.971.1841619
2026-09-25UTHR475.640.970.1741634
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-08-28UTHR515.22-2.7- 26.04
2026-08-31UTHR510.68-2.7- 26.04
2026-09-01UTHR512.70-2.7- 26.04
2026-09-02UTHR492.24-2.7- 26.04
2026-09-03UTHR489.24-2.7- 26.04
2026-09-04UTHR487.77-2.7- 26.04
2026-09-08UTHR498.10-2.7- 26.04
2026-09-09UTHR506.89-2.7- 26.04
2026-09-10UTHR503.98-2.7- 26.04
2026-09-11UTHR497.28-2.7- 26.04
2026-09-14UTHR503.01-2.7- 26.04
2026-09-15UTHR500.34-2.7- 26.04
2026-09-16UTHR500.34-2.7- 26.04
2026-09-17UTHR497.43-2.7- 26.04
2026-09-18UTHR494.65-2.7- 26.04
2026-09-21UTHR493.24-2.7- 26.04
2026-09-22UTHR497.36-2.7- 26.04
2026-09-23UTHR488.99-2.7- 26.04
2026-09-24UTHR472.11-2.7- 26.04
2026-09-25UTHR475.61-2.7- 26.07
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-08-28UTHR-51.78-1.215.10
2026-08-31UTHR-51.93-1.315.10
2026-09-01UTHR-52.08-1.315.10
2026-09-02UTHR-52.23-1.315.10
2026-09-03UTHR-52.38-1.315.10
2026-09-04UTHR-52.23-1.315.10
2026-09-08UTHR-51.83-1.315.10
2026-09-09UTHR-51.99-1.315.10
2026-09-10UTHR-51.98-1.315.10
2026-09-11UTHR-51.83-1.314.97
2026-09-14UTHR-51.68-1.334.97
2026-09-15UTHR-51.83-1.334.97
2026-09-16UTHR-51.99-1.334.97
2026-09-17UTHR-51.83-1.334.97
2026-09-18UTHR-51.83-1.334.97
2026-09-21UTHR-51.52-1.264.97
2026-09-23UTHR-51.83-1.264.97
2026-09-24UTHR-51.83-1.264.97
2026-09-25UTHR-51.67-1.266.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

7.27

Avg. EPS Est. Current Quarter

6.46

Avg. EPS Est. Next Quarter

6.7

Insider Transactions

-51.67

Institutional Transactions

-1.26

Beta

0.5

Average Sales Estimate Current Quarter

786

Average Sales Estimate Next Quarter

791

Fair Value

504.38

Quality Score

100

Growth Score

91

Sentiment Score

8

Actual DrawDown %

22

Max Drawdown 5-Year %

-33

Target Price

637.92

P/E

17.01

Forward P/E

16.52

PEG

2.32

P/S

6.46

P/B

3.17

P/Free Cash Flow

18.72

EPS

27.96

Average EPS Est. Cur. Y​

26.07

EPS Next Y. (Est.)

28.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

41.56

Relative Volume

0.8

Return on Equity vs Sector %

-5.8

Return on Equity vs Industry %

14.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

◆ UTHR Healthcare
$475.45
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
21/25
Volume
7/15
Valuation
18/20
TP/AR
1/10
Options
5/10
RSI
34.2
Range 1M
14.1%
Sup Dist
1.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
39 /100
WEAK
Momentum
17/25
Growth
10/30
Estimates
6/20
Inst/Vol
1/15
Options
5/10
EPS Yr
-6.3%
EPS NY
10.2%
52W%
34.3%
💎
Long-Term Value
Quality companies, undervalued
52 /100
WEAK
🟡 HOLD +24.8% upside
Quality
25/30
Valuation
9/30
Growth
7/25
Stability
8/10
LT Trend
3/5
Upside
+24.8%
Quality
100
MoS
6%
UTHR — P/E HistoricalBiotechnology
United Therapeutics Corporation
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1400
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
UTHR

Latest News

—
Caricamento notizie per UTHR…
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading